Webinar

ASG’s Northeastern regional webinar on ATTR amyloidosis, recorded on July 10, 2021. The webinar is presented by: Gustavo Buchele, MD, PhD, Medical Director, Ionis Pharmaceutical Inc.

Dr. Morie Gertz, hematologist at the Mayo Clinic, leads a discussion of the Andromeda drug trial of daratumumab (brand name Darzalex) and related topics regarding light chain (AL) amyloidosis treatment.

Introduction to Light Chain (AL) Amyloidosis Webinar presented by Muriel Finkel, President of Amyloidosis Support Groups.

It is a presentation by Dr. Raymond Comenzo on the history and future of AL management at the XV International Symposium on Amyloidosis.

ASG’s Northeastern regional webinar on ATTR amyloidosis, recorded on July 10, 2021. The webinar is presented by: Jeffrey Cehelsky, BS Pharm, MBA, Vice President of Development Operations, Intellia Therapeutics.

Amyloidosis Support Groups’ webinar for light chain (AL) amyloidosis patients and caregivers in the Northeast region on September 18, 2021. Led by ASG President Muriel Finkel, this webinar discusses the current treatments for light chain amyloidosis and features amyloidosis expert: Laura M. Dember, MD, Nephrologist and Professor of Medicine at the Hospital of the University

Amyloidosis Support Groups webinar on AL amyloidosis from October 29, 2022. Led by ASG President Muriel Finkel, featured speaker Anita D’Souza, MD, Hematologist/Oncologist, Associate Professor, Medical College of Wisconsin, Milwaukee, WI, talks about IMiDS, Alkylators & Anti-Fibril Drugs.

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, discusses treatment options for light chain (AL) amyloidosis, including how the results of the ANDROMEDA study (NCT03201965) evaluating daratumumab plus CyBorD may represent a new approach to patients with amyloidosis. This interview was recorded via an online conference call with The

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, discusses treatment options for light chain (AL) amyloidosis, including how the results of the ANDROMEDA study (NCT03201965) evaluating daratumumab plus CyBorD may represent a new approach to patients with amyloidosis. This interview was recorded via an online conference call with The

Monica Fawzy Bryant, co-founder of Triage Cancer, provides a detailed overview and answers questions on health insurance considerations for patients with amyloidosis.